Controversies in liver transplantation
Timothy M. McCashland – 19 October 2005
Langerhans' cell histiocytosis after living donor liver transplantation: Report of a case
Ryoko Honda, Yasuharu Ohno, Takuya Iwasaki, Sadayuki Okudaira, Masahiko Okada, Akira Kamitamari, Koichi Ohshima, Hiroyuki Moriuchi, Takashi Kanematsu – 19 October 2005 – We report a case of Langerhans' cell histiocytosis (LCH) occurring after a living donor liver transplantation (LDLT) for fulminant hepatitis. A 9‐month‐old girl underwent an LDLT for fulminant hepatitis of an unknown cause. The histology of the native liver did not show any findings of LCH. On postoperative day 42, her Epstein‐Barr virus (EBV)‐DNA and cytomegalovirus antigenemia were both found to be positive.
Pretransplant survival is shorter in HIV‐positive than HIV‐negative subjects with end‐stage liver disease
Margaret V. Ragni, Bijan Eghtesad, Kimberly W. Schlesinger, Igor Dvorchik, John J. Fung – 19 October 2005 – Despite improved survival after liver transplantation (OLTX) in HIV‐positive individuals treated with highly active antiretroviral therapy (HAART), some transplant candidates do not survive to OLTX. To determine if pretransplant outcome is related to severity of liver disease and/or HIV infection, we prospectively evaluated 58 consecutive HIV‐positive candidates seen at a single center from 1997‐2002.
Neonatal hemochromatosis: It's OK to say “NO” to antioxidant‐chelator therapy
Mike A. Leonis, William F. Balistreri – 19 October 2005
Oxygenation during hypothermic rat liver preservation: An in vitro slice study to demonstrate beneficial or toxic oxygenation effects
Nils A. 't Hart, Arjan van der Plaats, Alexander Faber, Henri G.D. Leuvenink, Peter Olinga, Janneke Wiersema‐Buist, Gijsbertus J. Verkerke, Gerhard Rakhorst, Rutger J. Ploeg – 19 October 2005 – Hypothermic machine perfusion (HMP) of abdominal organs is shown to be superior compared to cold storage. However, the question remains if oxygenation is required during preservation as oxygen is essential for energy resynthesis but also generates toxic reactive oxygen species (ROS).
When shouldn't we retransplant?
Michael A. Zimmerman, R. Mark Ghobrial – 19 October 2005
Neonatal hemochromatosis — medical treatment vs. transplantation: The king's experience
Fernanda Rodrigues, Marcia Kallas, Ruth Nash, Paul Cheeseman, Lorenzo D'Antiga, Mohamed Rela, Nigel D. Heaton, Giorgina Mieli‐Vergani – 19 October 2005 – The aim of our study was to compare the outcome of medical treatment vs. liver transplantation in infants with neonatal hemochromatosis (NH) referred to King's College Hospital from 1990‐2002. We conducted a retrospective review of 19 children from 14 families. Fifteen children presented at birth and 4 during the first week of life. One child was diagnosed by cordocentesis at 30 weeks of gestation.
Access to liver transplantation: Can we do a better job?
Thomas V. Cacciarelli – 19 October 2005
Living donor liver transplantation for biliary atresia complicated by situs inversus: Technical highlights
Kentaro Matsubara, Yasuhiro Fujimoto, Hideya Kamei, Kohei Ogawa, Mureo Kasahara, Mikiko Ueda, Hiroto Egawa, Yasutsugu Takada, Masaki Kitajama, Koichi Tanaka – 19 October 2005 – Living‐donor liver transplantation (LDLT) has become an established technique to treat children with end‐stage liver disease. Biliary atresia (BA), one of the most common indications for liver transplantation in children, can be associated with situs inversus (SI). In the past, the presence of SI has been considered to be an absolute contraindication for liver transplantation because of the technical difficulties.